

09 Feb 2024 | Analysis

China Biotech Podcast: Shanghai Policy, US Draft Biosecure Bill, MNCs' China Strategy

Policy, Legislation And Business

by Brian Yang

Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.

The Shanghai government is aiming to spur investment in three areas, including biotech, which is slated to receive additional funding from the major Chinese city.

What are some of the implications of the policy? (Also see "*Shanghai's Latest Policy To Boost VC/PE Activities Amid Sector Downturn*" - Scrip, 25 Jan, 2024.)

Meanwhile, a US House draft bill, Biosecure, is aimed at restricting Chinese gene sequencing and bio service providers from participating in US government contracts, causing <u>WuXi Biologics</u>' Hong Kong-listed shares to tumble.

What could be some of the long term impacts on the biotech sector? (Also see "<u>US Draft Bill Highlights Perceived China Biotech Threat</u>" - Scrip, 30 Jan, 2024.)

Scrip UK-based managing editor Kevin Grogan also joins Brian Yang to discuss his recent coverage of <u>AstraZeneca PLC</u> and <u>Sanofi</u>, in which executives of these multinationals shed light on their views of China, rising Chinese innovation and other challenges.



<u>Click here to explore this interactive content online</u> [≯] ☆

